Calvo AM, et al. – Researchers planned this study to assess the possible relationship of polymorphisms in the CYP2C8*3 and CYP2C9 genes with the clinical efficacy of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer’s overall satisfaction. They concluded that slow metabolizers of piroxicam, who were volunteers with mutant alleles, were indifferent from normal metabolizers with the wild–type alleles and hence did not need specialized piroxicam doses to manage postoperative pain and inflammation.